Market Research Expert

Global Market for Complex Regional Pain Syndrome Therapeutics to be Driven by Increasing Number of Clinical Trials

Press Release   •   May 24, 2016 05:45 EDT

A new market research report by Transparency Market Research offers an in-depth analysis of the global market for complex regional pain syndrome therapeutics, focusing on the product segmentation, key drivers and restraints, major geographical segments, and competitive landscape. The research study, titled “Complex Regional Pain Syndrome (CRPS) Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020,” further talks about the major challenges and opportunities in this market.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2500

The research study further presents estimated figures and historical statistics of the global CRPS therapeutics market with the help of tables, infographics, graphs, and charts. The study also provides recommendations and inputs given by industry experts in order to guide the decision-makers and players in formulating effective business strategies. The research study has been classified on the basis of product type, end use, and geography. The market size, share, and forecast figures for each segment have been included in the research study.

CRPS is an uncommon form of chronic pain that mostly affects a leg or an arm. This condition is characterized by vasomotor instability, limited range of motion, swelling, patchy bone demineralization, pain, and skin color changes. CRPS usually develops after a surgery, injury, or heart stroke, but the pain is completely out of proportion in comparison with the severity of the primary injury. CRPS is caused mostly as a result of a malfunction and failure of peripheral in the central nervous system, due to which it is sometimes referred to as reflex sympathetic dystrophy syndrome.

Browse Report: http://www.transparencymarketresearch.com/complex-regional-pain-syndrome-therapeutics.html

CRPS is categorized into two similar forms: CRPS type 1 (reflex sympathetic dystrophy or RSD) and CRPS type 2 (Causalgia). Type 1 CRPS is used in the context of individuals who have confirmed nerve injuries, while type 2 CRPS is used to refer to patients who do not have any confirmed nerve injury. In CRPS, the nervous systems mostly affect many other systems in the human body at the same time, due to which the development of drugs for treatment has been a difficult task for researchers. Nevertheless, the growing knowledge base in medicine and neurology offers unique market opportunities for drugs and products in the global CRPS therapeutics market.

At present, there is no cure for the CRPS condition but drug therapies are helping in easing the pain associated with the disease and reducing the progression of this condition. In addition, the rising number of clinical trials and drug development are expected to help introduce new drugs and therapeutics in the next few years.

Some of the prominent players operating in the global market for CRPS therapeutics are GlaxoSmithKline plc, Cell Targeting Technologies, CeNeS Pharmaceuticals plc, King Pharmaceuticals Inc., Endo Pharmaceuticals, Pfizer, Inc., Bayer AG, Abiogen Pharma S.p.A., Eli Lilly & Co., Danish Pain Research Center, Forest Laboratories Inc., Amgen Inc., Celgene Corporation, and NeurogesX, Inc.

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.